Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | CETP | P11597 | 14/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898988 | 0.91 | CETP (0.46) | SLC6A2SLC6A4CETPSCN9A | |
| SCHEMBL993396 | 0.86 | CETP (0.52) | CETP | |
| SCHEMBL992981 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4CETPSCN9A | |
| SCHEMBL992716 | 0.81 | SLC6A2 (0.54) | SLC6A2SLC6A4CETPLMNASCN9A | |
| SCHEMBL993969 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4CETPLMNASCN9A | |
| SCHEMBL994051 | 0.80 | CETP (0.44) | SLC6A2SLC6A4CETP | |
| SCHEMBL1565408 | 0.78 | CETP (0.61) | CETP | |
| SCHEMBL994913 | 0.78 | CETP (0.45) | SLC6A2SLC6A4CETP | |
| SCHEMBL6855337 | 0.78 | SLC6A2 (0.61) | SLC6A2SLC6A4CETPLMNASCN9A | |
| SCHEMBL993065 | 0.77 | SLC6A2 (0.60) | SLC6A2SLC6A4CETPLMNASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071210-B2 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. (US) | 2006-07-04 | — | — | US | disclosed |
| WO-2005117869-A1 | COMBINATIONS COMPRISING (S)-AMLODIPINE AND A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION | SEPRACOR INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20040053842-A1 | Methods of treatment with CETP inhibitors and antihypertensive agents | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053842-A1 | Methods of treatment with CETP inhibitors and antihypertensive agents | CETP, APOB, MTTP | SLC6A2 187/4885SLC6A4 414/4885CETP 1/4885 |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | CETP, MTTP, APOB | SLC6A2 903/4885SLC6A4 1292/4885CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.